Recombinant Human TACI/TNFRSF13B Fc Chimera Protein, CF Summary
Accession # Q53F36
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in sterile PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
TACI, transmembrane activator and CAML-interactor, is a member of the TNF receptor superfamily. TACI is a type III membrane protein with an extracellular N‑terminus in the absence of a cleaved signal sequence. The extracellular region of TACI contains two cysteine rich domains. Within the TNFRSF, it shares the highest homology with BCMA. TACI and BCMA have both been shown to bind APRIL and BAFF, members of the TNF ligand superfamily. TACI is expressed on the cell surface of B cells and activated, but not resting, T cells. Analogous to BCMA, data suggests that TACI may play an important role in B cell development, function and regulation. Human TACI is a 293 amino acid (aa) protein consisting of a 166 aa extracellular domain, a 20 aa transmembrane domain, and a 107 aa intracellular domain. Human and mouse TACI share 54% amino acid identity.
- Xia, X.-Z. et al. (2000) J. Exp. Med. 192:137.
- von Bulow, G.U. et al. (1997) Science, 278:138.
- Gross, J.A. et al. (2000) Nature 404:995.
- Marsters, S.A. et al. (2000) Curr. Biol. 10:785.
- Yan, M. et al. (2000) Nature Immunol. 1:37.
- Wu, Y. et al. (2000) J. Biol. Chem. 275:35478.
Citations for Recombinant Human TACI/TNFRSF13B Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 3
Filter your results:
APRIL and BAFF: novel biomarkers for central nervous system lymphoma
Authors: M Mulazzani, M Huber, S Borchard, S Langer, B Angele, E Schuh, E Meinl, M Dreyling, T Birnbaum, A Straube, U Koedel, L von Baumga
J Hematol Oncol, 2019;12(1):102.
Sample Types: Whole Cells
Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.
Authors: Isik G, Sliepen K, van Montfort T, Sanders R
PLoS ONE, 2014;9(9):e107683.
Sample Types: Protein
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Authors: Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human TACI/TNFRSF13B Fc Chimera Protein, CF
Average Rating: 5 (Based on 5 Reviews)
Have you used Recombinant Human TACI/TNFRSF13B Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image